

High burden of disease and associated costs for eosinophilic gastrointestinal diseases: Results from an online patient-centered research network Apred

Evan S. Dellon, MD MPH,^{1,2} Xiangfeng Dai, PhD,² Ellyn Kodroff,³ Mary Jo Strobel,⁴ Amy Zicarelli,⁵ Sarah Gray, 6 Amanda Cordell, 7 Girish Hiremath, MBBS MPH, 8 Elizabeth T. Jensen, MPH PhD^{2,9}



egidpartners.org

1 Center for Esophageal Diseases and Swallowing; 2 University of North Carolina School of Medicine; 3 Campaign Urging Research for Essinophilic Disease (CURED); 4 American Partnership for Essinophilic Disorders (APFED); ⁵Eosinophilic Family Coalition (EFC); ⁶AusEE Inc., ⁷EOS Network, ⁸Vanderbilt University Medical Center, ⁹Wake Forest University School of Medicine

Introduction

- · Data regarding health care-related costs and the burden of disease for non-EoE eosinophilic gastrointestinal diseases (EGIDs) are lacking, particularly from the patient perspective.
- · We aimed to determine the patient-reported health care burden of disease and costs related to care for non-EoE EGIDs.

Methods

- · Study design: Case-control pilot study based in EGID Partners (egidpartners.org), an online patientcentered research network designed and implemented by patient advocacy groups (PAGs) and EGID researchers and launched in 2020 (Figure 1).
- · Subjects: Recruited via emails and social media, directed messages to EGID patients through medical record patient portals, webinars, and by physicians.
- · Adults (≥18 years) with EGIDs, non-EGID adult controls, and these same groups but for caregivers of children <18 years of age could join.
- · Data: Subjects completed surveys on demographics, disease and medical history, and a burden of disease questionnaire. This instrument recorded patientreported healthcare utilization over the prior year related to heath care visits and procedures, as well as out-of-pocket costs/payments.

 Analysis: We calculated the median total costs and number of visits overall, and also compared these between adults and pediatric (care give report) cases.

Results

- We analyzed 58 non-EoE EGID patients with health care utilization data (mean (SD) age 29 (19) years; 69% female; 95% white; 88% with an atopic condition; mean (SD) 7.4 (9.9) years of symptoms prior to diagnosis).
- · Of the non-EoE EGID cases, 13 had eosinophilic gastritis (EoG), 17 had eosinophilic enteritis (EoN), 6 had eosinophilic colitis (EoC), and 22 had multiple areas of overlap; additionally, 27 had esophageal involvement.

Figure 1: EGID Partners website



Table 1: Non-EoE EGID costs overall, and by adult patient compared to caregiver of the pediatric patient

	Overall non- EoE EGID population (n = 58)	Adult report (n = 42)	Caregiver report (n = 16)	р
Health care encounters (median [IQR])				
Total number of encounters	12 (5-33)	12 (5-29)	13.5 (6-33.5)	0.81
Outpatient visits	5 (3-15)	5 (3-19)	5 (3-15)	0.65
Urgent care/ER/hospital	3 (2-5)	3 (1-3)	3.5 (2-9)	0.32
Endoscopies	2 (1-3)	2 (2-3)	2 (1-3)	0.43
Testing	5 (3-12)	5 (3-12)	4 (1-7)	0.27
Costs in USD (median [IQR])				
Total costs	\$1000 (\$100- \$3570)	\$1050 (\$100- \$3600)	\$350 (\$0- \$2600)	0.57
Outpatient visits	\$250 (\$0- \$1845)	\$500 (\$0- \$1846)	\$250 (\$0- \$1000)	0.87
Urgent care/ER/hospital	\$215 (\$0- \$1200)	\$230 (\$0- \$1800)	\$200 (\$0- \$300)	0.69
Testing	\$400 (\$0- \$1400)	\$525 (\$0- \$1400)	\$225 (\$0- \$2750)	1.0
Medications (EGID-related)	\$325 (\$100- \$1010)	\$400 (\$100- \$1010)	\$135 (\$100- \$440)	0.37

- · The median number of health care visits over the prior year was 12 (IQR: 5-33; range 1-90), with a median of 5 outpatient doctor visits, 3 urgent care/ED visits or hospitalizations, and 2 endoscopy visits
- Results were similar for adult patient report (n=42) or caregiver report for pediatric patients (n=16).

- The annual median out-of-pocket costs were \$1000 (IQR: \$100-\$3570; range: 0-\$100,400). Median costs for outpatient visits, testing, and medications were \$250, \$400, and \$325, respectively (Table 1).
- · Costs were similar for adult patients and caregivers (Table 1).

Conclusions

- · Patients with non-EoE EGIDs experience a high health care burden, with frequent health care encounters (median of 1 encounter/month) and substantial out-pocket costs (median of \$1000/year).
- Both adult and pediatric providers must maintain awareness of the substantial burden in costs to EGID patients, including challenges for patients to manage their disease given these costs.
- · Future investigations should include out-of-pocket costs, such as the ones found here, when burden of disease is assessed.

References

- Jensen ET, Kappelman MD, Kim HP, et al. Early Life Exposures as Risk Factors For Pediatric Eosinophi
- Jensen ET, Kappelman MD, Kim HP, et al. Early Life Exposures as Risk Factors For Pediartic Eosinophilic Esophagitis. A Pilot and Feasibility Sudu's J Pediartic Asstroenterlon Vitus (2013;5:76:77-10.
 Delion ES, Shaheen O, Koutlas NT, et al. Early life factors are associated with risk for eosinophilic esophagitidigenosed in adulthood. Die Esophagus 2021;3:40:eaa074.
 Jensen ET, Kuhl JT, Martin LJ, et al. Prenafal, infrapartum, and postnatal factors are associated with pediatric cosinophilic esophagitis. J Allergo (Clin Immunol 2016;41:214-62.
- Jensen ET, Kuhl JT, Martin LJ, et al. Early life environmental exposures interact with genetic su

Funded by an investigator-initiated grant from Takeda, and used resources from UNC CGIBD (NIH P30 DK034987). We also acknowledge Allakos and Ellodi as EGID Partners sponsors, and thank all patients for participating in EGID Partners